

REMARKS

Claims 1-33 are pending.

The Examiner contends that the pending claims encompass eight distinct inventions as follows, and requires election of one of them.

Group I: Claims 1-7, drawn to a truncated DEC1/Stra 13 polypeptide lacking the DEC1/Stra 13 repressor domain;

Group II: Claim 8, drawn to an isolated nucleic acid encoding a truncated DEC1/Stra 13 polypeptide lacking the DEC1/Stra 13 repressor domain;

Group III: Claims 9-13, drawn to a method of inhibiting adipogenesis comprising contacting a cell with a truncated DEC1/Stra 13 polypeptide lacking the DEC1/Stra 13 repressor domain;

Group IV: Claims 14-18, drawn to a method of inhibiting PPAR γ 2 promoter activity comprising contacting a cell with a truncated DEC1/Stra 13 polypeptide lacking the DEC1/Stra 13 repressor domain;

Group V: Claims 19-24, drawn to a method of inhibiting angiogenesis in a tumor comprising contacting the tumor with a truncated DEC1/Stra 13 polypeptide lacking the DEC1/Stra 13 repressor domain;

Group VI: Claims 25-28, drawn to a method of inhibiting angiogenesis in an angiogenesis-related disease comprising contacting at least one cell with a truncated DEC1/Stra 13 polypeptide lacking the DEC1/Stra 13 repressor domain;

Group VII: Claims 29-31, drawn to a method of identifying a DEC1/Stra 13 agonist comprising contacting a test compound with a cell comprising a reporter gene operably linked to a PPAR γ 2 proximal promoter fragment, and comparing reporter gene expression in the presence of the test compound with reporter gene expression in the presence of a truncated DEC1/Stra 13 polypeptide lacking the DEC1/Stra 13 repressor domain; and

Group VIII: Claims 32-33, drawn to a method of identifying a PPAR γ 2 agonist comprising contacting a test compound with a mammalian cell comprising a functional PPAR γ 2 gene and comparing the amount of PPAR γ 2 polypeptide in the presence of the test compound with the amount of PPAR γ 2 polypeptide in the presence of a known PPAR γ 2 agonist.

In addition, the Examiner has required election of a single SEQ ID NO: for further prosecution.


In response, Applicants elect Group III, claims 9-13, without prejudice to the prosecution of the subject matter of non-elected claims in other patent applications, and without traverse.

Further, as required, Applicants elect SEQ ID NO:7, without prejudice to the prosecution of non-elected SEQ ID NOs in other patent applications, and without traverse. Claims which read on this SEQ ID NO: are claims 9-13.

An early allowance is earnestly requested.

Respectfully submitted,

BAKER BOTTS, LLP.

A handwritten signature in black ink, appearing to read "Lisa B. Kole", is written over a horizontal line.

Lisa B. Kole

Patent Office Reg. No. 35,225

Dated: June 6, 2007

30 Rockefeller Plaza
New York, New York 10112

Attorneys for Applicant
(212) 408-2628